References
- Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007;13:2436–41.
- Maluf DG, Fisher RA, King AL, Gibney EM, Mas VR, Cotterell AH, et al. Hepatitis C virus infection and kidney transplantation: predictors of patient and graft survival. Transplantation 2007;83:853–7.
- Scott DR, Wong JK, Spicer TS, Dent H, Mensah FK, McDonald S, et al. Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand. Transplantation 2010;90:1165–71.
- Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335–74.
- Farnik H, Zeuzem S. New antiviral therapies in the management of HCV infection. Antivir Ther 2012;17:771–83.
- Dumortier J, Guillaud O, Gagnieu MC, Janbon B, Juillard L, Morelon E, et al. Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: is it feasible? J Clin Virol 2013; 56:146–9.
- Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359–62.
- Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958–65.
- Mistik R. Investigation of the epidemiology of viral hepatitis in Turkey. In: Tekeli E, Balık I, Tabak F. Viral hepatitis 2007 pp 10–50.
- Akpolat T, Arik N, Gunaydin M, Utas C, Dilek K, Caglar S, et al. Prevalance of anti-HCV among haemodialysis patients in Turkey: a multicentre study. Nephrol Dial Transplant 1995;10:479–80.
- Pereira BJ, Natov SN, Bouthot BA, Murthy BV, Ruthazer R, Schmid CH, et al. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int 1998;53:1374–81.
- Vachon ML, Dieterich DT. The era of direct-acting antivirals has begun: the beginning of the end for HCV? Semin Liver Dis 2011;31:399–409.
- Leroy V, Serfaty L, Bourlière M, Bronowicki JP, Delasalle P, Pariente A, et al. Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver. Liver Int 2012;32:1477–92.